{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T16:10:52Z","timestamp":1779120652070,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,9,11]],"date-time":"2017-09-11T00:00:00Z","timestamp":1505088000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s10620-017-4745-1","type":"journal-article","created":{"date-parts":[[2017,9,11]],"date-time":"2017-09-11T14:14:18Z","timestamp":1505139258000},"page":"3110-3116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Biologic Agents Are Associated with Excessive Weight Gain in Children with Inflammatory Bowel Disease"],"prefix":"10.1007","volume":"62","author":[{"given":"Leonard","family":"Haas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Chevalier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittny T.","family":"Major","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felicity","family":"Enders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5949-3717","authenticated-orcid":false,"given":"Jeanne","family":"Tung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,11]]},"reference":[{"key":"4745_CR1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1365-277X.2011.01171.x","volume":"24","author":"K Gerasimidis","year":"2011","unstructured":"Gerasimidis K, McGrogan P, Edwards CA. The aetiology and impact of malnutrition in paediatric inflammatory bowel disease. J Hum Nutr Diet. 2011;24:313\u2013326.","journal-title":"J Hum Nutr Diet"},{"key":"4745_CR2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.clnu.2010.07.019","volume":"30","author":"R Vadan","year":"2011","unstructured":"Vadan R, Gheorghe LS, Constantinescu A, et al. The prevalence of malnutrition and the evolution of nutritional status in patients with moderate to severe forms of Crohn\u2019s disease treated with Infliximab. Clin Nutr. 2011;30:86\u201391.","journal-title":"Clin Nutr"},{"key":"4745_CR3","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.dld.2003.12.014","volume":"36","author":"O Borrelli","year":"2004","unstructured":"Borrelli O, Bascietto C, Viola F, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn\u2019s disease. Dig Liver Dis. 2004;36:342\u2013347.","journal-title":"Dig Liver Dis"},{"key":"4745_CR4","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","volume":"132","author":"J Hyams","year":"2007","unstructured":"Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn\u2019s disease in children. Gastroenterology. 2007;132:863\u2013873.","journal-title":"Gastroenterology"},{"key":"4745_CR5","first-page":"A209","volume":"130","author":"M Issa","year":"2006","unstructured":"Issa M, Weber L, Shidham S, et al. Infliximab significantly increases proportion of overweight\/obese Crohn\u2019s disease patients receiving longterm maintenance therapy. Gastroenterology. 2006;130:A209.","journal-title":"Gastroenterology"},{"key":"4745_CR6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10067-011-1863-6","volume":"31","author":"RA Brown","year":"2012","unstructured":"Brown RA, Spina D, Butt S, et al. Long-term effects of anti-tumour necrosis factor therapy on weight in patients with rheumatoid arthritis. Clin Rheumatol. 2012;31:455\u2013461.","journal-title":"Clin Rheumatol"},{"key":"4745_CR7","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1529-8019.2011.01439.x","volume":"24","author":"LD Renzo","year":"2011","unstructured":"Renzo LD, Saraceno R, Schipani C, et al. Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-alpha treatment. Dermatol Ther. 2011;24:446\u2013451.","journal-title":"Dermatol Ther"},{"key":"4745_CR8","first-page":"1","volume":"11","author":"RJ Kuczmarski","year":"2000","unstructured":"Kuczmarski RJ, Ogden CL, Guo SS, et al. CDC growth charts for the United States: methods and development. Vital Health Stat. 2000;11:1\u2013190.","journal-title":"Vital Health Stat"},{"key":"4745_CR9","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1002\/ibd.21585","volume":"17","author":"MD Long","year":"2011","unstructured":"Long MD, Crandall WV, Leibowitz IH, et al. Prevalence and epidemiology of overweight and obesity in children with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:2162\u20132168.","journal-title":"Inflamm Bowel Dis"},{"key":"4745_CR10","first-page":"855","volume":"35","author":"K Briot","year":"2008","unstructured":"Briot K, Gossec L, Kolta S, et al. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment. J Rheumatol. 2008;35:855\u2013861.","journal-title":"J Rheumatol"},{"key":"4745_CR11","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1111\/j.1468-3083.2012.04571.x","volume":"27","author":"V Florin","year":"2013","unstructured":"Florin V, Cottencin AC, Delaporte E, et al. Body weight increment in patients treated with infliximab for plaque psoriasis. J Eur Acad Dermatol Venereol. 2013;27:e186\u2013e190.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4745_CR12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3899\/jrheum.130159","volume":"41","author":"A Shafferman","year":"2014","unstructured":"Shafferman A, Fontaine KR, Cron RQ, et al. Changes in body mass index in children with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors. J Rheumatol. 2014;41:113\u2013118.","journal-title":"J Rheumatol"},{"key":"4745_CR13","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1136\/ard.2008.088773","volume":"67","author":"MA Gonzalez-Gay","year":"2008","unstructured":"Gonzalez-Gay MA, Garcia-Unzueta MT, Berja A, et al. Anti-tumour necrosis factor alpha therapy modulates ghrelin in patients with severe rheumatoid arthritis. Ann Rheum Dis. 2008;67:1644\u20131646.","journal-title":"Ann Rheum Dis"},{"key":"4745_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-0115(02)00305-1","volume":"111","author":"SP Kalra","year":"2003","unstructured":"Kalra SP, Bagnasco M, Otukonyong EE, et al. Rhythmic, reciprocal ghrelin and leptin signaling: new insight in the development of obesity. Regul Pept. 2003;111:1\u201311.","journal-title":"Regul Pept"},{"key":"4745_CR15","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/rheumatology\/keh055","volume":"43","author":"M Otero","year":"2004","unstructured":"Otero M, Nogueiras R, Lago F, et al. Chronic inflammation modulates ghrelin levels in humans and rats. Rheumatology. 2004;43:306\u2013310.","journal-title":"Rheumatology"},{"key":"4745_CR16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ygcen.2012.01.009","volume":"177","author":"EW Roubos","year":"2012","unstructured":"Roubos EW, Dahmen M, Kozicz T, et al. Leptin and the hypothalamo-pituitary-adrenal stress axis. Gen Comp Endocrinol. 2012;177:28\u201336.","journal-title":"Gen Comp Endocrinol"},{"key":"4745_CR17","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/MPG.0b013e3181f87a95","volume":"52","author":"B Aurangzeb","year":"2011","unstructured":"Aurangzeb B, Leach ST, Lemberg DA, et al. Assessment of nutritional status and serum leptin in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2011;52:536\u2013541.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"4745_CR18","first-page":"530","volume":"85","author":"RL Fawcett","year":"2000","unstructured":"Fawcett RL, Waechter AS, Williams LB, et al. Tumor necrosis factor-alpha inhibits leptin production in subcutaneous and omental adipocytes from morbidly obese humans. J Clin Endocrinol Metab. 2000;85:530\u2013535.","journal-title":"J Clin Endocrinol Metab"},{"key":"4745_CR19","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1210\/jc.2004-1222","volume":"90","author":"D Franchimont","year":"2005","unstructured":"Franchimont D, Roland S, Gustot T, et al. Impact of infliximab on serum leptin levels in patients with Crohn\u2019s disease. J Clin Endocrinol Metab. 2005;90:3510\u20133516.","journal-title":"J Clin Endocrinol Metab"},{"key":"4745_CR20","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/MEG.0b013e3282202bca","volume":"19","author":"K Karmiris","year":"2007","unstructured":"Karmiris K, Koutroubakis IE, Xidakis C, et al. The effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2007;19:789\u2013794.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"4745_CR21","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.autrev.2014.07.001","volume":"13","author":"M Versini","year":"2014","unstructured":"Versini M, Jeandel PY, Rosenthal E, et al. Obesity in autoimmune diseases: not a passive bystander. Autoimmun Rev. 2014;13:981\u20131000.","journal-title":"Autoimmun Rev"},{"key":"4745_CR22","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/S0016-5085(17)30838-7","volume":"152","author":"S Singh","year":"2017","unstructured":"Singh S, Facciorusso A, Singh AG, et al. Obesity is associated with inferior response to anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review and meta-analysis. Gastroenterology. 2017;152:S154.","journal-title":"Gastroenterology"},{"key":"4745_CR23","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/ibd.20069","volume":"13","author":"TD Walters","year":"2007","unstructured":"Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn\u2019s disease. Inflamm Bowel Dis. 2007;13:424\u2013430.","journal-title":"Inflamm Bowel Dis"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-017-4745-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-017-4745-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-017-4745-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,20]],"date-time":"2017-10-20T08:32:09Z","timestamp":1508488329000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-017-4745-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["4745"],"URL":"https:\/\/doi.org\/10.1007\/s10620-017-4745-1","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,11]]}}}